title: Characterization of tumor-associated Chk2 mutations.
abstract: The integrity of the DNA damage response pathway is essential for prevention of neoplastic transformation. Several proteins involved in this pathway including p53, BRCA1, and ATM are frequently mutated in human cancer. Checkpoint kinase 2 (Chk2) is a DNA damage-activated protein kinase that lies downstream of ATM in this pathway. Recently, heterozygous germline mutations in Chk2 have been identified in a subset of patients with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype, suggesting that Chk2 is a tumor suppressor gene. In this study, we have reported the biochemical characterization of the four tumor-associated Chk2 mutants. Two of the reported Chk2 mutations identified in Li-Fraumeni syndrome result in loss of Chk2 kinase activity. Whereas one mutation within the Chk2 forkhead homology-associated (FHA) domain, R145W, retains some basal kinase activity, this mutant cannot be phosphorylated at an ATM-dependent phosphorylation site (Thr-68) and cannot be activated following gamma radiation. Wild-type Chk2 exists mainly in a protein complex of M(r) approximately 200,000 whereas the R145W mutant forms a larger, presumably inactive complex in the cell. The other FHA domain mutant, I157T, behaves as wild-type Chk2 in all the assays used here. Because the FHA domain is involved in protein-protein interactions, this mutation may affect associations of Chk2 with other proteins. Additionally, we have shown that Chk2 can also be inactivated by down-regulation of its expression in cancer cells. Thus, Chk2 may be inactivated by multiple mechanisms in the cell.
authors.affiliation: Guggenheim 1342, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: S R
authors.initials: SR
authors.lastname: Webster
authors.forename: J
authors.initials: J
authors.lastname: Chen
mesh_terms: D002471:Cell Transformation, Neoplastic / Q000235:genetics; D064447:Checkpoint Kinase 2; D003110:Colonic Neoplasms / Q000201:enzymology / Q000235:genetics*; D016368:Frameshift Mutation; D005720:Gamma Rays; D006801:Humans; D016864:Li-Fraumeni Syndrome / Q000201:enzymology / Q000235:genetics*; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism / Q000528:radiation effects; D011494:Protein Kinases / Q000235:genetics* / Q000378:metabolism / Q000528:radiation effects; D017346:Protein Serine-Threonine Kinases; D011994:Recombinant Proteins / Q000378:metabolism
chemical_list: D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D011494:Protein Kinases; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases